<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d471" origId="Drotrecogin alfa"><sentence id="DrugDDI.d471.s0" origId="s0" text="Drug interaction studies with Xigris have not been performed in patients with severe sepsis."><entity charOffset="30-36" id="DrugDDI.d471.s0.e0" origId="s0.p2" text="Xigris" type="drug"/><negationtags>&lt;xcope&gt;Drug interaction studies with Xigris have &lt;cue&gt;not&lt;/cue&gt; been performed in patients with severe sepsis&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d471.s1" origId="s1" text="However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis."><entity charOffset="59-65" id="DrugDDI.d471.s1.e0" origId="s1.p15" text="Xigris" type="drug"/><entity charOffset="99-105" id="DrugDDI.d471.s1.e1" origId="s1.p21" text="Xigris" type="drug"/><entity charOffset="125-130" id="DrugDDI.d471.s1.e2" origId="s1.p24" text="drugs" type="drug"/><pair e1="DrugDDI.d471.s1.e0" e2="DrugDDI.d471.s1.e1" id="DrugDDI.d471.s1.p0" interaction="false"/><pair e1="DrugDDI.d471.s1.e0" e2="DrugDDI.d471.s1.e2" id="DrugDDI.d471.s1.p1" interaction="false"/><pair e1="DrugDDI.d471.s1.e1" e2="DrugDDI.d471.s1.e2" id="DrugDDI.d471.s1.p2" interaction="true"/></sentence><sentence id="DrugDDI.d471.s2" origId="s2" text="Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products."><entity charOffset="93-100" id="DrugDDI.d471.s2.e0" origId="s2.p33" text="heparin" type="drug"/><entity charOffset="102-124" id="DrugDDI.d471.s2.e1" origId="s2.p35" text="unfractionated heparin" type="drug"/><entity charOffset="152-164" id="DrugDDI.d471.s2.e2" origId="s2.p40" text="prophylactic" type="drug"/><entity charOffset="174-203" id="DrugDDI.d471.s2.e3" origId="s2.p41" text="low molecular weight heparins" type="drug"/><pair e1="DrugDDI.d471.s2.e0" e2="DrugDDI.d471.s2.e1" id="DrugDDI.d471.s2.p0" interaction="false"/><pair e1="DrugDDI.d471.s2.e0" e2="DrugDDI.d471.s2.e2" id="DrugDDI.d471.s2.p1" interaction="false"/><pair e1="DrugDDI.d471.s2.e0" e2="DrugDDI.d471.s2.e3" id="DrugDDI.d471.s2.p2" interaction="false"/><pair e1="DrugDDI.d471.s2.e1" e2="DrugDDI.d471.s2.e2" id="DrugDDI.d471.s2.p3" interaction="false"/><pair e1="DrugDDI.d471.s2.e1" e2="DrugDDI.d471.s2.e3" id="DrugDDI.d471.s2.p4" interaction="false"/><pair e1="DrugDDI.d471.s2.e2" e2="DrugDDI.d471.s2.e3" id="DrugDDI.d471.s2.p5" interaction="false"/></sentence><sentence id="DrugDDI.d471.s3" origId="s3" text="Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial."><entity charOffset="41-48" id="DrugDDI.d471.s3.e0" origId="s3.p47" text="heparin" type="drug"/><entity charOffset="122-128" id="DrugDDI.d471.s3.e1" origId="s3.p57" text="Xigris" type="drug"/><pair e1="DrugDDI.d471.s3.e0" e2="DrugDDI.d471.s3.e1" id="DrugDDI.d471.s3.p0" interaction="false"/><negationtags>Concomitant use of prophylactic low dose heparin did &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; appear to affect safety&lt;/xcope&gt;, however, its effects on &lt;xcope&gt;the efficacy of Xigris have &lt;cue&gt;not&lt;/cue&gt; been evaluated in an adequate and well-controlled clinical trial&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d471.s4" origId="s4" text="Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays)."><entity charOffset="0-4" id="DrugDDI.d471.s4.e0" origId="s4.p65" text="Drug" type="drug"/><entity charOffset="41-47" id="DrugDDI.d471.s4.e1" origId="s4.p68" text="Xigris" type="drug"/><entity charOffset="75-81" id="DrugDDI.d471.s4.e2" origId="s4.p72" text="Xigris" type="drug"/><entity charOffset="183-194" id="DrugDDI.d471.s4.e3" origId="s4.p81" text="factor VIII" type="drug"/><pair e1="DrugDDI.d471.s4.e0" e2="DrugDDI.d471.s4.e1" id="DrugDDI.d471.s4.p0" interaction="false"/><pair e1="DrugDDI.d471.s4.e0" e2="DrugDDI.d471.s4.e2" id="DrugDDI.d471.s4.p1" interaction="false"/><pair e1="DrugDDI.d471.s4.e0" e2="DrugDDI.d471.s4.e3" id="DrugDDI.d471.s4.p2" interaction="false"/><pair e1="DrugDDI.d471.s4.e1" e2="DrugDDI.d471.s4.e2" id="DrugDDI.d471.s4.p3" interaction="false"/><pair e1="DrugDDI.d471.s4.e1" e2="DrugDDI.d471.s4.e3" id="DrugDDI.d471.s4.p4" interaction="false"/><pair e1="DrugDDI.d471.s4.e2" e2="DrugDDI.d471.s4.e3" id="DrugDDI.d471.s4.p5" interaction="false"/></sentence><sentence id="DrugDDI.d471.s5" origId="s5" text="This interference may result in an apparent factor concentration that is lower than the true concentration."/><sentence id="DrugDDI.d471.s6" origId="s6" text="Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays)."><entity charOffset="0-6" id="DrugDDI.d471.s6.e0" origId="s6.p94" text="Xigris" type="drug"/><entity charOffset="106-115" id="DrugDDI.d471.s6.e1" origId="s6.p103" text="factor II" type="drug"/><pair e1="DrugDDI.d471.s6.e0" e2="DrugDDI.d471.s6.e1" id="DrugDDI.d471.s6.p0" interaction="false"/><negationtags>Xigris present in plasma samples does &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; interfere with one-stage factor assays based on the PT (such as factor II&lt;/xcope&gt;, V, VII, and X assays).</negationtags></sentence></document>